For Q1 FY2026 ended March 31, 2026, Evolus reported revenue of $73.1 million, up 6.7% year-over-year. Net loss improved to $10.7 million from $18.9 million a year ago, a 43.5% reduction. Operating loss narrowed to $6.8 million from $15.1 million, and diluted EPS improved to -$0.16 from -$0.30. The company had $49.8 million in cash, negative equity of $28.8 million, and long-term debt of $156.4 million.
•Revenue grew 6.7% YoY to $73.1 million.
•Net loss improved 43.5% to $10.7 million.
•Operating loss narrowed 54.9% to $6.8 million.
•Cash stood at $49.8 million with long-term debt of $156.4 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults
Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes. Incorporated in 2012, the company is headquartered in Newport Beach, California.
What does Evolus, Inc. (EOLS) do and what are its main products?
Evolus, Inc. is a performance beauty company that operates in the cash-pay aesthetic market. Its primary product is Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation. Jeuveau is used for the temporary improvement in the appearance of moderate to severe glabellar lines (frown lines between the eyebrows) in adults. Additionally, Evolus offers Evolysse, a collection of injectable hyaluronic acid gels. The Evolysse line includes products designed for various facial areas such as the mid face, nasolabial folds, lips, and eyes. These products are used for aesthetic enhancement and wrinkle reduction. The company focuses on providing non-surgical aesthetic treatments to consumers seeking cosmetic improvements.
Where is Evolus, Inc. (EOLS) listed and in which currency does it trade?
Evolus, Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol EOLS. Its shares are traded in United States Dollars (USD). As a company headquartered in the United States and listed on a major U.S. exchange, its stock is accessible to investors through U.S. brokerage accounts. The NasdaqGM is a tier of the Nasdaq Stock Market that includes companies meeting certain financial and liquidity requirements. Trading in USD means that the stock price and financial results are denominated in the U.S. dollar, which is relevant for investors considering currency exposure.
What sector and industry does Evolus, Inc. (EOLS) belong to?
Evolus, Inc. operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification indicates that the company is involved in the development, manufacturing, and marketing of pharmaceutical products, with a focus on specialty and generic drugs. In Evolus's case, its products are aesthetic treatments, including botulinum toxin and hyaluronic acid fillers, which are considered specialty pharmaceuticals. The company's focus on the cash-pay aesthetic market distinguishes it from traditional pharmaceutical companies that may rely on insurance reimbursement. As a specialty drug manufacturer, Evolus targets specific medical and cosmetic needs, such as wrinkle reduction and facial volume restoration.
Where is Evolus, Inc. (EOLS) headquartered and which markets does it serve?
Evolus, Inc. is headquartered in Newport Beach, California, United States. The company serves markets in the United States, Canada, Europe, and Australia. Its geographic presence spans multiple continents, indicating a global reach in the aesthetic market. The company's products, such as Jeuveau and Evolysse, are available to consumers in these regions through healthcare providers. Being based in California places Evolus in a region known for its focus on beauty and wellness, which aligns with its business of providing aesthetic treatments. The international expansion into Europe and Australia suggests that the company is targeting markets with demand for non-surgical cosmetic procedures.
How does Evolus, Inc. (EOLS) generate revenue and what is its business model?
Evolus, Inc. generates revenue by selling its aesthetic products directly to healthcare providers, such as dermatologists, plastic surgeons, and medical spas, in the cash-pay market. This means that consumers pay out-of-pocket for treatments rather than relying on insurance. The company's main revenue driver is Jeuveau, a botulinum toxin type A product used for treating glabellar lines. Additionally, Evolus offers Evolysse, a line of hyaluronic acid dermal fillers for facial rejuvenation. By focusing on the cash-pay aesthetic market, Evolus avoids the complexities of insurance reimbursement and pricing pressures from third-party payers. The company's business model emphasizes direct sales and marketing to practitioners, along with consumer education to drive demand for its branded products.